Publications by authors named "P Abenia Uson"
Background: Spontaneous regression (SR) of cancer remains a rare phenomenon, particularly in hepatocellular carcinoma (HCC), where limited literature exists. This case report emphasizes the significance of SR in advanced HCC, shedding light on the proposed mechanisms and addressing the scarcity of documented cases in current medical literature.
Case Description: We present the case of a 67-year-old female with a history of localized HCC who underwent right hepatectomy.
A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Expert Opin Drug Saf
November 2023
Introduction: Pemigatinib is a selective small-molecule inhibitor of the fibroblast growth factor receptor (FGFR) 1-3. FGFR is associated with increased cell division, proliferation, and survival. Inhibition of this receptor is an effective treatment against tumors driven by activated fusions in FGFR2.
View Article and Find Full Text PDFBackground Detection of pathogenic germline variants (PGVs) has implications for cancer screening, prognosis, treatment selection, clinical trial enrollment, and family testing. Published guidelines provide indications for PGV testing, determined by clinical and demographic factors, but their applicability in an ethnically and racially diverse community hospital population is unknown. This study describes the diagnostic and incremental yield of universal multi-gene panel testing in a diverse population in a community cancer practice.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of perioperative chemotherapy in patients with colorectal cancer liver metastasis (CRLM), as its role remains unclear despite previous trials.
- After analyzing data from seven randomized controlled trials involving 1,504 patients, the results indicated that adding perioperative therapy leads to better disease-free survival (DFS) but does not significantly improve overall survival (OS).
- The review suggests that while perioperative systemic treatments can enhance DFS, decisions about their use should consider individual patient risks and benefits.
Background: Morreton virus (MORV) is an oncolytic Vesiculovirus , genetically distinct from vesicular stomatitis virus (VSV).
Aim: To report that MORV induced potent cytopathic effects (CPEs) in cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC) in vitro models.
Approach And Results: In preliminary safety analyses, high intranasal doses (up to 10 10 50% tissue culture infectious dose [TCID 50 ]) of MORV were not associated with significant adverse effects in immune competent, non-tumor-bearing mice.